ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
The H63D Polymorphism in the HFE Gene Promotes Aggressive Disease Phenotypes in Pancreatic Ductal Adenocarcinoma.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
purposeControversy exists regarding the association between HFE H63D polymorphism and pancreatic ductal adenocarcinoma (PDAC). This study initially assessed the frequency of H63D in patients with PDAC and subsequently investigated correlations between genotype and disease phenotype. EXPERIMENTAL
designH63D prevalence was determined by genotyping 795 patients with PDAC from two retrospective cohorts of unselected (n = 389) or surgically resected (n = 171) individuals and one prospective cohort of resectable cases (n = 235). Associations between H63D status and clinicopathologic variables were retrospectively evaluated in unselected patients and prospectively validated in surgical candidates. The phenotypic impact of H63D carriage was also investigated using a genetically engineered KCh67d murine model and PDAC cell lines. Spatial transcriptomics was applied to human PDAC samples to define genotype-associated microenvironmental and cell-cycle alterations.
resultsH63D prevalence was higher in patients with resectable PDAC (37.7%, 37.4%, and 34% across cohorts) than in those with unresectable disease (22.4%) or the general population (24.1%). Despite this, resected H63D-carriers had significantly worse outcomes, with the variant emerging as an independent predictor of shorter disease-free survival (P = 0.002). Consequently, KCh67d mice developed earlier, larger tumors with increased metastatic spread. H63D PDAC cells and tumor spatial transcriptomic showed enhanced invasiveness, G1-phase accumulation, and TGFβ-independent epithelial-mesenchymal transition (EMT) activation.
conclusionsThe H63D variant is strongly associated with PDAC resectability and, paradoxically, with a poorer postsurgical outcome. Activation of a TWIST1-dependent EMT program within a G1-enriched cellular context underlies the more aggressive phenotype of H63D PDAC, possibly accounting for the clinical conundrum.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.